BLOG

Fierce-Biotech

Elicio’s therapeutic cancer vaccine boosts T-cell therapy response in mice while biotech awaits phase 2 data

As Elicio Therapeutics awaits a phase 2 readout of its lymph node-targeting therapeutic cancer vaccine in humans, the biotech has published fresh preclinical data showing the same tech boosted the efficacy of T cell receptor-modified T-cell (TCR-T) therapy in mice.

Back to the Blog .st0{stroke:#000;stroke-width:3}.st0,.st1{fill:none}